Nasus Pharma Ltd (NSRX) Form 6-K — Aug 17, 2026
Nasus Pharma reported a first-half 2026 net loss of $5.9 million, up 375% from $1.3 million a year earlier, with R&D spending up 796% to $2.6 million on the NS002 intranasal epinephrine program and G&A up 554% to $3.4 million largely from public-company costs. Loss per share was $0.54 versus $0.17. Despite a $15.0 million gross February 2026 private placement that lifted cash, equivalents and short-term deposits to $11.9 million at June 30, management concluded there is substantial doubt about the company's ability to continue as a going concern. Cash stood at roughly $10.3 million as of August 17, 2026, and is expected to fund operations only through the second quarter of 2027.
Key figures
- Guidance
- Existing cash expected to be sufficient to fund operations through the second quarter of 2027
- Net Income
- -$5.942 million (H1 2026) vs -$1.252 million (H1 2025)
- Total Assets
- $12.449 million
- Cash Position
- $11.9 million (cash, equivalents and short-term deposits at June 30, 2026; ~$10.3 million as of August 17, 2026)
- Shares Outstanding
- 11710808
- Working capital
- $10.9 million
- Ga expense h1 2026
- $3.452 million, up 554% YoY
- Loss per share yoy
- -$0.54 vs -$0.17
- Rd expense h1 2026
- $2.589 million, up 796% YoY
- Accumulated deficit
- $24.462 million
- Ipo gross proceeds 2025
- $10.0 million at $8.00/share
- Ns002 market opportunity
- $2 billion (per CEO quote)
- Operating cash use h1 2026
- $6.036 million
- Feb2026 private placement gross
- $15.0 million ($13.7 million net)
- Warrant exercise potential proceeds
- $17.6 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.